Since March 23rd, two three-day tests have been conducted in Leda, Lanzhou. It is necessary to provide negative proof of nucleic acid within 48 hours, and conduct 1 nucleic acid test within 24 hours after arrival. If you can't provide negative proof of nucleic acid test within 48 hours, you need to carry out nucleic acid test twice within 3 days after arrival, and carry out home health monitoring before the results of nucleic acid test come out.
Extended information:
From March 23rd, the high-risk area of Xiuchuan Street in Qilihe District of Lanzhou City was isolated for 14 days. During the centralized isolation period, 1 nucleic acid detection was conducted every three days until 14 days after leaving the risk area. When the isolation is released, double sampling and double inspection shall be carried out.
From March 23, Laida, Xiuchuan Street, Qilihe District, Lanzhou City, was isolated at home for 7 days. During the period of home isolation, nucleic acid detection was carried out on days 1, 3, and 7, until leaving the township where the risk area is located for 7 days. When the quarantine was lifted, double sampling and double inspection were carried out.
From March 23rd, Laida, Qilihe District, Lanzhou City carried out 7-day home health monitoring. During the period of home health monitoring, nucleic acid detection was carried out on 1, 3, and 7 days until leaving the county where the risk area is located for 7 days.
Recommended reading: What are the common adverse reactions of vaccination in COVID-19?
According to the clinical trial results of Xinguan pneumonia vaccine and the information collected during emergency use, the common adverse reactions of COVID-19 vaccine in China are basically similar to those of other vaccines that have been widely used. Common adverse reactions are mainly manifested as swelling, induration and pain at the inoculation site, as well as clinical manifestations such as fever, fatigue, nausea, headache and muscle aches. Relevant departments will continue to strengthen the real-time monitoring and evaluation of adverse reactions.